Biohaven Ltd. (NYSE:BHVN) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Biohaven Ltd. (NYSE:BHVN) by 27.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 26,500 shares of the company’s stock after purchasing an additional 5,677 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Biohaven were worth $637,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Janus Henderson Group PLC boosted its stake in shares of Biohaven by 12.1% during the 4th quarter. Janus Henderson Group PLC now owns 6,982,425 shares of the company’s stock worth $260,735,000 after purchasing an additional 756,032 shares during the last quarter. Stifel Financial Corp boosted its stake in shares of Biohaven by 0.8% during the 4th quarter. Stifel Financial Corp now owns 6,559,313 shares of the company’s stock worth $244,990,000 after purchasing an additional 50,052 shares during the last quarter. Suvretta Capital Management LLC boosted its stake in shares of Biohaven by 8.1% during the 4th quarter. Suvretta Capital Management LLC now owns 5,620,271 shares of the company’s stock worth $209,917,000 after purchasing an additional 421,052 shares during the last quarter. Farallon Capital Management LLC boosted its stake in shares of Biohaven by 21.6% during the 4th quarter. Farallon Capital Management LLC now owns 4,428,167 shares of the company’s stock worth $165,392,000 after purchasing an additional 785,578 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Biohaven by 11.1% during the 4th quarter. Geode Capital Management LLC now owns 1,905,366 shares of the company’s stock worth $71,182,000 after purchasing an additional 190,754 shares during the last quarter. 88.78% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Robert W. Baird decreased their target price on shares of Biohaven from $60.00 to $57.00 and set an “outperform” rating on the stock in a research report on Monday, April 28th. William Blair raised shares of Biohaven to a “strong-buy” rating in a research report on Thursday, April 24th. Royal Bank Of Canada cut shares of Biohaven from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $54.00 to $21.00 in a research report on Monday, May 19th. JPMorgan Chase & Co. decreased their target price on shares of Biohaven from $68.00 to $55.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 18th. Finally, Cantor Fitzgerald raised shares of Biohaven to a “strong-buy” rating in a research report on Tuesday, May 13th. One analyst has rated the stock with a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $58.46.

Biohaven Stock Performance

NYSE BHVN opened at $15.08 on Thursday. Biohaven Ltd. has a one year low of $12.79 and a one year high of $55.70. The company’s 50 day moving average price is $14.68 and its 200 day moving average price is $23.14. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of -1.61 and a beta of 0.98.

Biohaven (NYSE:BHVN) last posted its quarterly earnings results on Monday, May 12th. The company reported ($2.17) EPS for the quarter, missing the consensus estimate of ($1.67) by ($0.50). Sell-side analysts forecast that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.